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Actividad fungicida sobre Candida albicans de una variante
de péptido sintético derivada de una fosfolipasa A2
RESUMEN
pEM-2, una variante de péptido sintético derivada de la miotoxina II, un homólogo de la fosfolipasa A2 presente en el veneno de la serpien-
te Bothrops asper, ha mostrado en estudios previos una potente actividad bactericida debida a la combinación de aminoácidos catiónicos e
hidrófobos en su secuencia, incluyendo tres residuos sustituidos por triptófano. Este estudio describe que el pEM-2 también ejerce una po-
tente actividad fungicida contra una variedad de especies de Candida clínicamente relevantes, matando el 100% de las levaduras a concen-
traciones cercanas a 10 mg/l (5 µM), mediante ensayos de recuento en placas. De tal modo, este péptido muestra una acción antimicrobiana
de amplio espectro, en ausencia de actividad hemolítica. La acción fungicida del pEM-2 sobre Candida es parcialmente inhibida por concen-
traciones crecientes de cationes divalentes extracelulares (Ca+2 o Mg+2), en concordancia con su mecanismo de acción propuesto, permeabi-
lizante de membranas.
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SUMMARY
pEM-2, a 13-mer synthetic peptide variant derived from myotoxin II, a phospholipase A2 homologue present in Bothrops asper snake venom,
has shown potent bactericidal activity in previous studies due to the combination of cationic and hydrophobic amino acids, including three
tryptophan-substituted residues in its sequence. This study reports that pEM-2 also exerts potent fungicidal activity against a variety of clini-
cally relevant Candida species, killing 100% of yeasts at concentrations near 10 mg/l (5 µM), as indicated by plate counting assays. Thus, this
peptide displays a broad-spectrum antimicrobial activity, in the absence of hemolytic activity. The fungicidal action of pEM-2 against Candida
can be partially inhibited by increasing concentrations of extracellular divalent cations (Ca+2 or Mg+2), in agreement with its proposed mem-
brane-permeabilizing mechanism of action.
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INTRODUCTION
Infectious diseases are among the leading causes of
death worldwide, especially in the less developed nations.
The rise in the number of immunocompromised patients
due to the AIDS epidemic, the use of anticancer drugs, as
well as immunosuppressive regimens in transplantation,
has led to an increase in fungal infections. Among them,
candidiasis is the most frequently observed clinical expres-
sion and Candida albicans is the predominant species re-
covered (1). Over the last decade, many Candida species
other than C. albicans have also emerged as pathogens of
clinical relevance (2) and drug resistance among these iso-
lates is of great concern (3). In addition, many of the cur-
rently available antifungal therapies have undesirable tox-
ic effects (4), and there is a great need for the development
of new classes of antimycotic agents and strategies.
Over the last two decades, an increasing number of
peptides with antimicrobial activity have been isolated from
various natural sources (5), emerging as potential new ther-
apeutic agents. The majority of these peptides can be cate-
gorized into four distinct structural classes: (a) extended
peptides with a high content of one (or two) amino acids
(e.g., histatins and indolicidin); (b) those that contain in-
tramolecular disulfide bonds, often stabilizing a predomi-
nantly β-sheet structure (e.g., defensins and protegrins); (c)
those with amphiphilic regions assuming an α-helical structure
(e.g., magainins and cecropins); and (d) the loop-structured
peptides like bactenecin (6). These antimicrobial peptides
are often cationic and amphipatic, and most of them kill
bacteria by permeabilizing the target cell membrane. Their
net positive charge presumably facilitates interactions with
negatively charged moieties present in membranes and/or
bacterial cell walls, whereas their amphiphilic character
enables membrane penetration and permeabilization (7). A
number of natural antifungal agents of proteinaceous na-
ture have been found in animal secretions such as saliva, in-
cluding lactoferrin, lysozyme and histatins. Synthetic pep-
tides derived from those proteins have shown high fungici-
dal potency against C. albicans (8) and other Candida spp.,
with the exception of C. glabrata (9).
Bothrops asper is a crotalid snake species distributed in
Central America and Southern Mexico (10). Its venom
contains a variety of phospholipases A2, including several
catalytically inactive phospholipase A2 homologues of the
Lys49 family such as myotoxin II (11). In previous studies,
a non-hemolytic 13-mer peptide (KKYRYYLKPLCKK),
derived from the C-terminal region of myotoxin II, showed
bactericidal activity against both Gram-positive and Gram-
negative strains (12). Ten synthetic peptide variants were
constructed and one of them, named pEM-2 (KKWR-
WWLKALAKK), with a triple Tyr→Trp and single CysAla
and Pro→Ala substitutions, showed high bactericidal po-
tency, endotoxin-neutralizing activity and, importantly, a
reduced toxicity upon muscle cells (13, 14). In this study,
we investigated the possible fungicidal effect of peptide
pEM-2 against a variety of Candida species, with the aim
of evaluating its potential as a novel antimycotic drug lead.
MATERIALS AND METHODS
Peptide synthesis
pEM-2 was synthesized by F-moc chemistry (15), pu-
rified by preparative reverse-phase HPLC to a purity of at
least 97% and analyzed by mass spectrometry to confirm
its sequence. Dry peptide was stored at –20 °C, and dis-
solved in 10 mM sodium phosphate buffer, pH 7.4, to a fi-
nal concentration of 50 mM immediately before the exper-
iments.
Candidacidal activity
To determine the minimal concentration of peptide
with fungicidal activity, a pilot experiment was performed
using a common laboratory strain of C. albicans (SC5314)
and a series of peptide dilutions (in 10 mM sodium phos-
phate pH 7.4). Antifungal activity was examined accord-
ing to the method of Edgerton et al. (16) with some modi-
fications. A loopful of the yeast was inoculated in yeast ni-
trogen base medium (YNB pH 6.8) (Difco Laboratories),
containing 4.5% of glucose, grown at 30 °C and harvested
in the mid-exponential phase by centrifugation at 2,100×g
for 10 min at room temperature. Cells were washed once
with phosphate-buffered saline (PBS) and twice in 10 mM
sodium phosphate buffer (pH 7.4) to a final concentration
of 1.8×105 yeast/ml. Twenty µl of cell suspension were
mixed with 20 mcl of pEM-2, at different concentrations
(ranging from 80 to 0.15 µg/ml in 2-fold dilutions), and in-
cubated for 90 min at 37 °C with shaking. Cells incubated
with 20 µl of phosphate buffer alone were used as a con-
trol. Finally, the suspensions were diluted by adding 360 µl
of YNB, and 40 µl were spread onto each of three Sa-
bouraud dextrose agar plates (pH 7.4) and incubated for 48 h
at 37 °C. Colonies were counted and the cell survival per-
centage was calculated as previously described (9).
Effect of divalent cations
Candidacidal experiments were performed as de-
scribed above, except that varying concentrations of Ca2+
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whereas Mg2+ causes a comparable inhibition at concen-
trations between 1 and 5 µM. The reduction in candidaci-
dal action of pEM-2 by divalent cations was dose-depen-
dent (Fig. 2). An inhibitory effect of Ca2+ and Mg2+ on the
activity of cationic peptides has also been documented for
histatins isolated from saliva (17) and indolicidin, a trypto-
phan-rich peptide (6). This inhibition likely depends on the
known stabilizing effect of Ca2+ or Mg2+ cations on mem-
branes, mediated through electrostatic interactions with an-
ionic sites of lipid components (18, 19).
In summary, the present results demonstrate that the
peptide pEM-2, in addition to its previously reported bac-
tericidal activity, is also able to exert potent fungicidal ef-
fects, which could be of interest to fight infections by Can-
dida spp. Its low molecular weight (1742.9), and hence
non-immunogenicity, as well as its relative ease of synthe-
sis (13 amino acids), make pEM-2 an interesting drug lead
for further evaluation of possible antifungal effects in vivo.
Its fungicidal activity is likely to involve the permeabiliza-
tion of fungal cell membrane, as suggested by the protec-
tive effects observed here with divalent cations, and in
agreement with the permeabilizing mechanism previously
shown for its bactericidal actions (12).
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and Mg2+ (0, 0.5, 5 and 25 mM) were added to the solu-
tions during the 90-min incubation of C. albicans SC5314
and pEM-2 at 5 µM concentration. 
RESULTS AND DISCUSSION
As shown in Fig. 1, pEM-2 caused a complete fungici-
dal effect at concentrations of 5 µM (10 mg/l) and higher.
In order to determine if this activity was also exerted upon
other Candida species, and since sensitivity to peptides
varies among them (9), we extended this assay to several
non-C. albicans species and other yeasts such as S. cere-
visiae, including the most frequently clinically isolated
strains (2). These included C. parapsilosis, C. guillier-
mondii, C. lusitanie, C. viswanathii, C. krusei, C. albicans
SC5314, C. glabrata, C. valida, C. tropicalis and C. kefyr;
S. cerevisiae and one C. albicans clinical isolate. We fol-
lowed the same protocol for cell preparation and tested the
peptide at 5 µM concentration to evaluate its fungicidal ac-
tivity. Interestingly, all of the strains tested were complete-
ly killed at this peptide concentration, indicating that all of
them were at least as sensitive as C. albicans SC5314, and
suggesting that pEM-2 is a potential antifungal agent with
a broad spectrum of activity.
Considering the potential clinical applications of this
peptide, we evaluated its fungicidal activity in the presence
of the two most abundant divalent cations, Ca2+ and Mg2+.
As shown in Fig. 2, the presence of Ca2+ at 0.5 µM con-
centration reduces by 50% the fungicidal activity of pEM-2,
Figure 1. Fungicidal activity of peptide pEM-2 against Candida albicans
SC5314. Yeasts were incubated with varying amounts of peptide (90 min
at 37 ºC) and then plated on Sabouraud dextrose agar for viable coun-
ting, in triplicates. Each point represents mean ± SD for each peptide con-
centration. The experiment was performed twice, with identical results.
Figure 2. Inhibition of the pEM-2-induced killing of Candida albicans
SC5314 by the presence of extracellular divalent cations. Yeast viability af-
ter incubation with pEM-2 (5 µM) in the absence of Ca+2 and Mg+2 was
0%. Each bar represents mean ± SD of three independent experiments.
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